After the successful clinical application and the approval of proteasomal inhibitors for the treatment of multiple myeloma, substantial progress has been made in understanding the molecular mechanisms of ubiquitin in cancer-relevant processes, and shed light on the therapeutic potential of the ubiquitin system [5]. This evidence concerns the gene UBC and plasma cell myeloma.